GlaxoSmithKline Appoints Faithful+Gould on £38m Stevenage Bioscience Catalyst

Dale Potts
Faithful+Gould has been appointed as the cost and procurement manager for the first phase of the prestigious £38m Stevenage Bioscience Catalyst.

Faithful+Gould has been appointed as the cost and procurement manager for the first phase of the prestigious £38m Stevenage Bioscience Catalyst, a partnership between GlaxoSmithKline, Wellcome Trust, East of England Development Agency, Department for Business, Innovation and Skills and the Technology Strategy Board.

The science park is intended to be one of the first purpose-built biomedical science open innovation campuses in the UK and should play a key role in re-energising the UK biotech sector.

This recent appointment follows an 18 month period of providing advice to GlaxoSmithKline during the masterplanning of the science park site.

The works comprise the construction of a fully fitted bio-incubator of 5,700 sq.m. and a shell & core accelerator building of 4,370sq.m together with associated external works.

The works have been awarded under an NEC (Third edition) contract and completion is due at the end of 2011.

An artist's impression of the Stevenage Bioscience Catalyst